Evidence map›Paper›PMID 38298739›Full record

ArticleJHEP reports : innovation in hepatology2024

Daan Andel, Lotte van den Bent, Marnix Gerard Ernest Hendrik Lam, Maarten Leonard Johannes Smits, Isaac Quintus Molenaar, Joep de Bruijne, Miangela Marie Laclé, Onno Kranenburg, Inne Hildbrand Max Borel Rinkes, Jeroen Hagendoorn

Open access · goldAbstract read
In one paragraph

Article in JHEP reports : innovation in hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Daan AndelDepartment of Surgical Oncology, University Medical Center Utrecht, Cancer Center, Utrecht, The Netherlands.
Lotte van den BentDepartment of Surgical Oncology, University Medical Center Utrecht, Cancer Center, Utrecht, The Netherlands.
Marnix Gerard Ernest Hendrik LamDepartment of Radiology and Nuclear Medicine, University Medical Center Utrecht, Cancer Center, Utrecht, The Netherlands.
Maarten Leonard Johannes SmitsDepartment of Radiology and Nuclear Medicine, University Medical Center Utrecht, Cancer Center, Utrecht, The Netherlands.
Isaac Quintus MolenaarDepartment of Surgical Oncology, University Medical Center Utrecht, Cancer Center, Utrecht, The Netherlands.
Joep de BruijneDepartment Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, the Netherlands.
Miangela Marie LacléDepartment of Pathology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Onno KranenburgDepartment of Surgical Oncology, University Medical Center Utrecht, Cancer Center, Utrecht, The Netherlands.
Inne Hildbrand Max Borel RinkesDepartment of Surgical Oncology, University Medical Center Utrecht, Cancer Center, Utrecht, The Netherlands.
Jeroen HagendoornDepartment of Surgical Oncology, University Medical Center Utrecht, Cancer Center, Utrecht, The Netherlands.
University Medical Center Utrecht · NLUtrecht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: High-dose unilobar radioembolization, or 'radiation lobectomy' (RL), is an induction therapy that achieves contralateral future liver remnant hypertrophy while simultaneously irradiating the tumor. As such, it may prevent further growth, but it is unknown whether RL affects intrahepatic lymphatics, a major route via which liver tumors disseminate. Methods: This was a case-control study conducted at University Medical Center Utrecht. The study compared lymph vessels in livers that had undergone RL (cases) with those in livers that had not undergone RL (controls). Histological samples were acquired from patients diagnosed with hepatocellular carcinoma (HCC) or colorectal liver metastases (CRLM) between 2017 and 2022. Lymph vessel morphology was analyzed by two researchers using podoplanin, a protein that is expressed in lymphatic endothelium. Results: Immunohistochemical analysis on post-RL tumor tissues from ten patients with CRLM and nine patients with HCC revealed aberrant morphology of irradiated liver lymphatics when compared to controls (n = 3 per group). Irradiated lymphatics were tortuous ( Conclusions: Radioembolization impairs peritumoral lymph vessel function. Further research is needed to evaluate if radioembolization impairs tumor dissemination via this route. Impact and implications: Unilobar radioembolization can serve as an alternative to portal venous embolization for patients who are considered unresectable due to an insufficient future liver remnant. This research suggests that radioembolization impairs the function of peritumoral liver lymph vessels, potentially hindering dissemination via this route. These findings provide support for considering unilobar radioembolization over standard portal venous embolization.

Indexed as

crlmhccImmunohistochemistryIntraoperative liver lymphangiographyLymphaticsRadiation lobectomyRadioembolization

Identifiers

PMID38298739
PMCPMC10827593
OpenAlexW4389328223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.